Successful management of a pregnancy complicated by essential thrombocythaemia with pegylated interferon

Jayasekara, W.M.N.D.; Abeyratne, S.; Kulathilake, Chandima; Gunawardena, Dammika; Wijesiriwardena, Indira

doi:10.4038/cmj.v60i2.8157

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Potential new treatments for ET are currently being developed and tested as a result of the discovery of the link between the JAK2 mutation and the incidence of ET. Pegylated interferon, a version of interferon with fewer side effects and easier administration, is being considered as a treatment option for high-risk individuals [11]. Recent trials have shown that ruxolitinib, a JAK inhibitor, has clinical benefits in patients with polycythemia vera who show an inadequate response, or unacceptable side effects, to therapeutic doses of hydroxyurea [12].…”

Section: Case Reportmentioning

confidence: 99%

Four Consecutive Recurrent Abortions in Patient with Essential Thrombocythemia

Seo

Park

Jeon

et al. 2017

Soonchunhyang Med Sci

View full text Add to dashboard Cite

Essential thrombocythemia (ET) is characterized by most cases in which platelet counts exceed 1 million/μL. ET is usually no symptoms during non-pregnancy, but arterial and venous thrombosis and hemorrhage may develop in pregnancy. Pregnancy in these patients is associated with many complications in both pregnant women and fetuses such as recurrent abortion, intrauterine fetal growth restriction, preterm delivery, preeclampsia, and stillbirth. In these patients, aspirin, low-molecular-weight heparin (LMWH), and interferon alpha (INF-α) are recommended during pregnancy. We report a case of four consecutive abortions despite being treated with INF-α, low dose aspirin, and LMWH in patient with ET.

show abstract

Section: Case Reportmentioning

confidence: 99%

Four Consecutive Recurrent Abortions in Patient with Essential Thrombocythemia

Seo

Park

Jeon

et al. 2017

Soonchunhyang Med Sci

View full text Add to dashboard Cite

show abstract

“…In addition, another successful high-risk pregnancy has been reported under treatment with Peg-IFN combined with ASA and LMWH. This was the only successful pregnancy, which produced a healthy baby since she has a history of miscarriages and pregnancy complications (stillbirth, hypertension, neonatal death) in the past [58,59].…”

Section: Pegylated Interferon-amentioning

confidence: 99%

Patients with essential thrombocytosis during pregnancy: Challenges and therapeutic dilemmas

Kanellopoulou¹

2017

Obstet Gynecol Rep

View full text Add to dashboard Cite

Treatment of patients with essential thrombocytosis during pregnancy is challenging and young women are reported to be at increased risk of first trimester abortions and other pregnancy complications. In literature, there are case reports and small case series where the treatment approach differs and the results are conflicting. The addition of low dose aspirin seems to be beneficial in most cases improving pregnancy outcome whereas interferon-a is the cytoreductive drug of choice when platelet control is needed during pregnancy. Anticoagulation with low-molecular weight heparin is not generally recommended and should be considered during the last few weeks of pregnancy and postpartum.

show abstract

Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy

Grießhammer

Sadjadian

Wille

2018

Expert Review of Hematology

View full text Add to dashboard Cite

The management of pregnancy during the course of BCR-ABL1-negative myeloproliferative neoplasms (MPN) is an increasingly relevant problem. This is mostly due to earlier and better diagnosis of MPN together with the trend in modern society toward delaying pregnancy until later life. Areas Covered: The present review aims to provide an overview of the available literature data concerning outcome of pregnancy in MPN. Possible therapeutic modalities are discussed and a management algorithm is suggested. Expert Commentary: Most data are available for women with essential thrombocythemia and we present 793 published pregnancies. Live birth rate is 68.5% with 31.5% miscarriages. Spontaneous abortion is the most frequent complication with 26.5%, followed by stillbirth with 4.8%. Maternal complications are relatively low with 1.8% major thrombotic and 2.4% major bleeding events. In polycythemia vera the situation is clinically more complex and roughly 150 pregnancy reports are available. There is very limited information in primary myelofibrosis with less than 20 reported pregnancies. With active management including control of blood counts, aspirin, low molecular weight heparin and in higher risk cases interferon alpha pregnancy in MPN is manageable with a success rate not far below the normal situation with 80%.

show abstract

Successful management of a pregnancy complicated by essential thrombocythaemia with pegylated interferon

Cited by 4 publications

References 6 publications

Four Consecutive Recurrent Abortions in Patient with Essential Thrombocythemia

Four Consecutive Recurrent Abortions in Patient with Essential Thrombocythemia

Patients with essential thrombocytosis during pregnancy: Challenges and therapeutic dilemmas

Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy

Contact Info

Product

Resources

About